Blocking MARCO in a syngeneic melanoma tumour model also reduces the suppressive effects of TAMs on NK cells and enhances the efficacy of T cell-focussed immunotherapies, such as PD-1/PD-L1 inhibitors [110]. The gene discussed is RPL17; the disease is neoplasm.